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Abstract Objectives: Determination
of activated partial thromboplastin
time (aPTT) is used in coagulation
management after heart surgery. Re-
sults from the central laboratory take
long to be obtained. We sought to
shorten the time to obtain coagulation
results and the desired coagulation
state and to reduce blood loss and
transfusions using point of care (POC)
aPTT determination. Design: Ran-
domized, controlled trial. Setting:
University-affiliated 20-bed surgical
ICU. Patients and participants:
Forty-two patients planned for valve
surgery (Valves) and 84 for coro-
nary artery bypass grafting (CABG)
with cardiopulmonary bypass. In-
terventions: Valves and CABG
were randomized to postoperative
coagulation management monitored
either by central laboratory aPTT
(Lab group) or by POC aPTT (POC
group). Heparin was administered
according to guidelines. Measure-
ments and results: POC aPTT results
were available earlier than Lab aPTT
after venipuncture in Valves (3 ± 2
vs. 125 ± 68 min) and in CABG
(3 ± 4 vs. 114 ± 62 min). Heparin
was introduced earlier in the POC
group in Valves (7 ± 23 vs. 13 ± 78 h,
p = 0.01). Valves of the POC group
bled significantly less than Valves
in the Lab group (647 ± 362 ml vs.
992 ± 647ml, p < 0.04), especially
during the first 8 h after ICU ad-
mission. There was no difference in
bleeding in CABG (1074 ± 869 ml
vs. 1102 ± 620, p = NS). In Valves,
fewer patients in the POC group
than in the Lab group needed blood
transfusions (1/21 vs. 8/21; p = 0.03).
No difference was detected in CABG.
Conclusions: In Valves in the POC
group the time to the desired coag-
ulation state was reduced, as was
the thoracic blood loss, reducing the
number of patients transfused. This
improvement was not observed in
CABG. Side effects were similar in
the two groups.
Keywords Quality · Cardiac surgery ·
Intensive care unit · Coagulation
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Introduction
Severe bleeding occurs occasionally after heart surgery
with cardiopulmonary bypass (CPB) [1]. Rapid assess-
ment of the coagulation state is required to identify the
causes of hemorrhages, such as platelet dysfunction,
residual heparin, coagulation factor depletion, hyperfibri-
nolysis and bleeding from surgical causes [1]. In addition,
patients after valve replacement surgery need early onset
and monitoring of therapeutic heparin treatment without
increasing bleeding.
The activated partial thromboplastin time (aPTT), mea-
sured in the central laboratory (Lab aPTT), is routinely
used to guide the management of postoperative coagula-
tion treatment. The time from venipuncture to availability
of the laboratory results can be as much as 2 h [2]. A pi-
lot study in our surgical intensive care unit (SICU) showed
similar results (136 ± 126 min). Besides, there is no evi-
dence that Lab aPTT is the most reliable test to assess the
bleeding risk and the coagulation state after CPB [1].
Point of care (POC) tests provide aPTT within 3 min
and have shown their accuracy in coronary care patients [3,
4, 5] and during CPB [6]. POC aPTT correlated poorly
with Lab aPTT in our context [7]. One author suggested
that POC aPTT could be a better predictor of post-CPB
bleeding risk [8].
We hypothesized that the management of heparin
administration by POC aPTT after CPB would decrease
the time to achieve the desired (anti-)coagulation state and
lead to a reduced blood loss and need for transfusions.
We compared, in a prospective, randomized, open
controlled trial, heparin treatment and anticoagulation
monitoring managed by POC aPTT and by Lab aPTT in
patients after heart surgery. Patients after coronary artery
bypass grafting (CABG) needing prophylactic heparin, and
patients after valve replacement surgery (Valve) needing
therapeutic heparin were analyzed separately. Preliminary
results of this study were presented at an international
meeting [9].
Materials and methods
The study was approved by the institutional ethics com-
mittee. Written informed consent was obtained from every
patient before surgery. The study was performed in the 20-
bed SICU, of a tertiary university teaching hospital.
Patients
Adult patients planned for elective CABG or valve surgery
with cardiopulmonary bypass were included. Patients with
bleeding disorders, hepatic dysfunction, chronic renal in-
sufficiency or on extracorporeal cardiac assistance or with
intra-aortic balloon pump were excluded (for details see
ESM).
Study design
We compared two different postoperative coagulation
management strategies guided either by Lab aPTT (Lab
group) or by POC aPTT (POC group) in Valves and CABG.
After randomization stratified by the type of surgery, we
assessed Lab aPTT in the Lab group, while we measured
both the POC aPTT and the Lab aPTT in the POC group.
The medical and nursing teams in charge of patients in the
POC group were blinded to the Lab aPTT results.
Endpoints
The primary endpoints were postoperative thoracic blood
loss, the number of patients needing postoperative transfu-
sions during their ICU stay and hemoglobin levels at ICU
discharge.
The secondary endpoints were the time from the ICU
admission to the onset of heparin treatment, the percent-
age of Lab aPTT and POC aPTT results within the desired
anticoagulation range, the amount of heparin/24 h admin-
istered per patient during ICU stay and the number of other
major bleedings, or thromboembolic events.
Laboratory and point of care coagulation assessment
Measurement of aPTT was performed at ICU admission
and then every 6 h, or 4 h after initiation of heparin and
after each dosage modification. aPTT was assessed within
the following hour in the case of administration of pro-
tamine, fibrinogen, fresh frozen plasma or platelet transfu-
sions, or in the presence of important thoracic blood losses
(> 250 ml/h for more than 1 h).
Lab aPTT, heparin activity, fibrinogen and prothrom-
bin time were tested by standard methods in the central
laboratory (for details see ESM). The central laboratory
is accredited in accordance with the ISO/IEC 17025 Stan-
dard (type C: methods development allowed) by the Swiss
Federal Office of Metrology and Accreditation (METAS,
Bern).
The three POC devices (CoaguChek® Pro; Roche
Diagnostics, Switzerland) were used according to
the manufacturer’s recommendations. Inter-operator,
inter-instrument and inter-cartridge variability were
satisfactory [7].
The anesthesia procedure, the intra-operative and the
postoperative coagulation/anticoagulation management
protocol and details of data collection are provided in the
ESM.
Indication for red blood cell transfusion
Red blood cells (RBCs) were transfused when the hema-
tocrit level was below 22% in patients after valve surgery
and below 24% after CABG. In the presence of myocardial
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ischemia or cardiogenic shock, the threshold was a hemat-
ocrit value of 28%.
Power calculation, randomization and statistical analysis
The study was designed to detect a clinically significant
reduction in the total thoracic blood loss at ICU discharge
i.e., of at least 350 ml (equivalent to one RBC). The
standard deviation (SD) estimates of ± 400 ml for Valves
and ± 570 ml for CABG were derived from the pilot study.
With an α = 0.05 and a power of 80%, the calculation
resulted in 21 patients in each group in Valves and 42
in CABG. A total of 126 patients were randomized by
a computer-generated randomization table with concealed,
opaque envelopes stratified according to the operation
type (Valves, CABG). For the statistical analysis, StatView
for Windows version 5.0.1® (SAS Institute Inc., Cary, NC,
USA) was used. All analyses were performed following
Table 1 Outcome data
Valves CABG
Lab group POC group p valuea Lab group POC group p valuea
(n = 21) (n = 21) (n = 42) (n = 42)
Blood loss, Hb and transfusions
at ICU discharge
Cumulative thoracic blood loss 992 ± 647 647 ± 362 0.04 1102 ± 620 1074 ± 869 0.86
(mean ± SD, ml)
Hemoglobin (mean ± SD, g/l) 9.3 ± 1.4 9.8 ± 1.2 0.27 9.7 ± 1.0 9.7 ± 1.3 0.79
Patients transfused with 8 (38) 1 (5) 0.02 8 (19) 5 (12) 0.55
RBC during ICU, n (%)
Patients transfused with 2 (10) 0 (0) 0.48 3 (7) 5 (12) 0.71
FFP during ICU, n (%)
Patients transfused with 0 (0) 0 (0) – 1 (2) 1 (2) > 0.99
platelets during ICU, n (%)
Patients treated with 1 (5) 0 (0) > 0.99 1 (2) 1 (2) > 0.99
protamine sulfate during ICU, n (%)
Surgical hemostasis, n (%) 0 (0) 0 (0) – 1 (2) 1 (2) > 0.99
Complications at hospital discharge
Non mediastinal hemorrhage / 0 (0) 0 (0) – 0 (0) 0 (0) –
blood loss, n (%)
Thromboembolic event, 0 (0) 0 (0) – 0 (0) 1 (2) > 0.99
n (%)
CABG occlusion, 0 (0) 0 (0) – 0 (0) 1 (2) > 0.99
n (%)
Length of:
ICU stay, [median (range), days] 2 (1–7) 2 (1–18) 0.66 2 (1–9) 2 (1–12) 0.34
Hospital stay, [median (range), days] 13 (8–24) 11 (8–62) 0.73 9 (2–24) 11 (5–34) 0.63
Death during:
ICU, n (%) 0 (0) 1 (5) > 0.99 2 (5) 0 (0) > 0.99
Hospital stay, n (%) 0 (0) 2 (10) 0.49 2 (5) 1 (2) > 0.99
RBC, red blood cells; FFP, fresh frozen plasma; a Calculated using ANOVA with Bonferroni correction, Fisher’s exact test or Mann–
Whitney U test as appropriate
intention to treat. Valves and CABG were analyzed and are
presented separately.
The agreement between Lab aPTT and POC aPTT and
the bleeding risk assessment was analyzed in patients in
which POC aPTT was performed (POC group) consider-
ing Valves and CABG together (63 patients). Further de-
tails on the statistical analysis are provided in the ESM.
Results
The flow diagram of patients included between July 2000
and February 2002 is summarized in Fig. E1 of the ESM.
Agreement between Lab aPTT and POC aPTT in Valves
and CABG
The overall agreement between Lab aPTT and POC
aPTT, assessed according to Bland and Altman, was
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Fig. 1 Cumulative thoracic blood loss (box plots) at 8, 24, and 48 h
after ICU admission and at ICU discharge in patients that under-
went valvular surgery (Valves) or coronary artery bypass grafting
(CABG) with coagulation management guided by central laboratory
aPTT (Lab group; light gray) or by point of care aPTT (POC group;
dark gray). In the box plots, the middle horizontal bars represent
median values, the squares represent the 25th and 75th percentiles,
the lower and upper bars represent the 10th and 90th percentiles,
and the circles represent minimum and maximal values. * p < 0.05
by ANOVA with Bonferroni correction
poor (–15.5 ± 30.6 s). The agreement between samples
drawn at ICU admission was worse (–27.0 ± 56.8 s) than
between those drawn thereafter (–14.2 ± 25.8 s).
Patient population
Patients’ characteristics before surgery and at ICU ad-
mission and data regarding surgery and cardio-pulmonary
bypass did not differ between the Lab and POC groups
(Tables E1 and E2 of the ESM) in Valves or CABG. The
Valves patients had the tendency to be younger (p = 0.07),
were less frequently males (p = 0.02), had undergone heart
surgery in the past more often (p = 0.001) and took less
frequently aspirin prior to the operation (p < 0.001). In
Valves CPB was shorter (p < 0.02), heparin and protamine
doses given during CPB were lower (p < 0.001 and
p < 0.004 respectively) and valves had less frequently
pleural drains (p < 0.001). In Valves the mean Lab aPTT
was higher (p < 0.04) and more heparin was delivered
during their ICU stay (p = 0.004).
Endpoints
Valves
The cumulative thoracic blood loss was significantly
lower in the POC group at each time during the ICU
stay and at discharge than in the Lab group (p < 0.05)
(Fig. 1). This difference became apparent during the first
8 h and persisted until ICU discharge. The hemoglobin at
ICU discharge was similar in the Lab and POC groups.
Significantly fewer patients in the POC group required
RBC transfusions during their ICU stay (Table 1). The
number needed to treat (NNT) to avoid one patient to
be transfused was 3. All transfused patients, except one
(Lab group), received their first transfusion within the first
12 h. The number of other blood products transfused was
similar in the Lab and POC groups (Table 1). The number
of surgical procedures needed for hemostasis did not differ
between the Lab and POC groups (Table 1).
No patient showed an extrathoracic blood loss, other
hemorrhages or thromboembolic events related to heparin
therapy (Table 1).
None of the outcome measures considered differed be-
tween the Lab and POC groups (Table 1). The duration
of endotracheal intubation did not differ between the two
groups [median (range): Lab group 9 h (0–17), POC group
8 h (0–264); p = 0.33].
The characteristics of the coagulation assessment dur-
ing the ICU stay of both groups are detailed in Table 2.
There were significant differences between the POC and
the Lab group regarding the coagulation assessments and
the heparin treatment during the ICU stay (Table 2). Dur-
ing the first 8 h, 6/21 patients in the Lab group and 15/21
in the POC group (p = 0.01) were put on heparin. Within
24 h, 19/21 patients in the Lab group and 21/21 patients in
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Table 2 Coagulation
Valves CABG
Lab group POC group p valuea Lab group POC group p valuea
(n = 21) (n = 21) (n = 42) (n = 42)
Coagulation assessments
during ICU stay
Number of Lab aPTT / 177 / – 255 / 272 293 / – 373 / 376
POC aPTT assessments, n
Lab aPTT (mean ± SD, s) 42 ± 13 47 ± 25 0.02 40 ± 14 37 ± 12 0.003
POC aPTT (mean ± SD, s) – 64 ± 36 – 53 ± 34
Lab aPTT in target range, n (%) 60 (34) 120 (47)b 0.007 125 (43) 176 (47)c 0.27
POC aPTT in target range, n (%) – 193 (71)b – 283 (74)c
Time, venipuncture to availability of 125 ± 68 3 ± 2 < 0.0001 114 ± 62 3 ± 4 < 0.0001
result (mean ± SD, min)
Time, venipuncture to corrective 201 ± 114 48 ± 84 < 0.0001 222 ± 185 102 ± 110 < 0.0001
action (mean ± SD, min)
Heparin treatment during ICU stay
ICU admission-first heparin 12.8 ± 8.8 6.8 ± 4.8 0.01 13.6 ± 10.1 10.9 ± 7.5 0.15
administration (mean ± SD, h)
Dose /24 h ICU stay 9.2 ± 6.1 15.3 ± 8.3 0.01 8.0 ± 6.6 9.1 ± 6.4 0.42
(mean ± SD, 103 IU)
Coagulation parameters
at ICU discharge
Platelets 158 ± 69 160 ± 68 0.92 145 ± 42 193 ± 61 0.008
(mean ± SD, g/l)
Prothrombin time 84 ± 10 89 ± 10 0.31 88 ± 14 87 ± 16 0.89
(mean ± SD, %)
Lab aPTT 46 ± 17 45 ± 12 0.79 38 ± 8 40 ± 17 0.38
(mean ± SD, s)
POC aPTT – 72 ± 50 – – 58 ± 43 –
(mean ± SD, s)
Fibrinogen 5.9 ± 1.9 4.7 ± 1.9 0.20 6.4±1.5 6.4 ± 1.8 0.97
(mean ± SD, g/l)
a Calculated using Student’s t-test, Fisher’s exact test or Mann–Whitney U test as appropriate b Lab aPTT in target vs. POC aPTT in target
in the POC group in Valves (p < 0.0001) c Lab aPTT in target vs. POC aPTT in target in the POC group in CABG (p < 0.0001)
the POC group were put on heparin (p = NS). In patients in
whom heparinization was postponed (at any moment), this
was due to results (Lab or POC aPTT) outside the proto-
col range in all cases. In those patients, aPTT was repeated
following the anticoagulation protocol (see ESM).
The thoracic blood loss during the first 8 h was less
in patients in whom heparin was started compared with
patients in whom it was not started (239 ± 123 ml vs.
442 ± 430 ml, p = 0.04). The thoracic blood loss in the
first 8 h in patients receiving heparin was in the POC
group 210 ± 102 ml (n = 15) and 314 ± 147 ml (n = 6)
in the Lab group (p = 0.078). The thoracic blood loss in
the first 8 h of patients not receiving heparin was almost
identical in the POC and Lab group.
CABG
The cumulative thoracic blood loss did not differ between
the two groups (Fig. 1), nor did the thoracic blood loss in
the different time intervals. No outcome measure differed
between the two groups (Table 1).
No patient showed extrathoracic blood loss or other
hemorrhages. Two patients in the POC group showed
a transient myocardial ischemic event that resolved totally
in less than 24 h.
There were significant differences between the POC
group and the Lab group regarding the coagulation assess-
ments and the heparin treatment during the ICU stay, and
coagulation parameters at ICU discharge (Table 2).
Bleeding risk assessment
In a multiple regression model, the thoracic blood loss
at ICU discharge of all groups correlated positively only
with the maximal activated clotting time during the CPB,
the total dose of protamine administered at the end of the
CPB, and the POC aPTT at ICU admission (Table 3). Lab
aPTT was not considered in the multiple regression model
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Table 3 Uni- and multivariate correlations for bleeding during the ICU stay
Univariate analysis Multivariate analysis
Coefficient 95% CI p Coefficient 95% CI p
Cardio-pulmonary bypass data
Cardio-pulmonary bypass time (min) 3.15 1.54–4.75 0.05 – – NS
Aortic cross-clamp time (min) 4.90 2.84–6.97 0.02 – – NS
Max. activated clotting time during CPB (s) 0.61 0.34–0.88 0.03 1.08 0.67–1.49 0.01
Total protamine dose (IU) 0.17 0.16–0.18 0.02 0.39 0.38–0.40 0.0002
ICU admission data
Platelet count at ICU admission (g/l) –2.47 –3.69– –1.25 0.05 – – NS
Prothrombin time at ICU admission (%) –10.47 –15.67– –5.27 0.05 – – NS
POC aPTT at ICU admission (s) 3.45 1.65–5.25 0.06 4.27 2.68–5.86 0.009
ICU stay data
Total heparin dosage during ICU stay (IU) 0.002 0.001–0.003 0.05 – – NS
CPB: cardio-pulmonary bypass. ICU: intensive care unit. POC aPTT: point of care activated partial thromboplastin time. CI: confidence
interval
because it showed a p > 0.1 in the simple regression
(coefficient 95 CI: –2.26 to 3.24, p = 0.86). However, even
if added in the final multiple regression model it was
not significantly correlated (coefficient 95 CI: –5.97 to
2.39, p = 0.67) and the other variables remained almost
identical. All variables analyzed are available in the ESM
(Table E3).
Discussion
The cause of abnormal or excessive bleeding after CPB
is multifactorial [1]. Several interventions were performed
to manage excessive perioperative blood loss, focusing on
identification and correction of coagulation anomalies, on
guidelines or on medications [1]. Most interventions used
a set of POC or laboratory tests to analyze and reduce ex-
cessive bleeding [10, 11, 12, 13, 14]. We extended our in-
tervention to all patients, including those “bleeding nor-
mally”.
The reduction in thoracic blood loss is not due to
shorter POC turnaround times. The differences in blood
loss occurred in the initial 8 h after ICU admission, during
which time no intervention (protamine administration, sur-
gical reexploration) was attempted. Our findings suggest
that the reduced thoracic blood loss is due to the ability
of the POC aPTT to better predict the bleeding tendency
and therefore to identify patients in whom heparin may
be introduced without increasing blood loss. Indeed, in
our study the POC aPTT at ICU admission was a good
and independent predictor of the subsequent bleeding
tendency, whereas the Lab aPTT was not. This seems to
confirm previous reports suggesting that POC and Lab
aPTT are measuring different aspects of hemostasis and
that a whole-blood coagulation test, such as the POC
aPTT, could be a better predictor of the bleeding tendency
than Lab aPTT [7, 8]. Lab aPTT is already known to
be a poor predictor of the bleeding tendency [15, 16].
Moreover, the difference between the POC group and the
Lab group in the thoracic blood loss in the first 8 h tended
(small sample size) to be significant only in patients
who received heparin. POC therefore permitted correct
identification of patients (Valves) in whom anticoagulation
could be introduced early without increasing their thoracic
blood loss and allowed withholding of anticoagulation
in those in whom it would have increased the blood loss
during the first 8 h after surgery. The same decision taken
on the basis of the Lab aPTT assessment resulted in
early anticoagulation with increased bleeding. Several
patients in whom anticoagulation was withheld in the Lab
group could probably have been put on heparin without
any bleeding risk. The Lab aPTT determination seems
accurate but cannot be considered as a reference measure
to decide whether or not to start heparin in the immediate
postoperative period. POC aPTT is not accurate in cardiac
surgery patients for measurement of “the” aPTT, but it
seems to have greater validity in deciding whether or not
to start heparin in the first postoperative hours.
In CABG we did not find a difference in thoracic blood
loss and transfusions. In CABG, heparin was introduced at
prophylactic doses and later after normalization of coagu-
lation parameters. The ability to better identify patients in
whom heparin may be introduced without increasing blood
loss seems less important in this situation.
The reduced time to initiation of heparin and the deliv-
ery of more heparin may be related to the other property of
the POC device, i.e. the short time to obtain results. This
permitted a shorter interval from the decision to measure
aPTT to the introduction of heparin.
The fact that earlier heparinization did not reduce
thromboembolic events could question its usefulness.
International guidelines [17, 18] recommend introduction
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of heparin after valvular surgery as soon as possible if
patients are not bleeding. Postoperatively the valves are
not epithelialized [17], and patients are in a hypercoagu-
lable state [19]. In patients who have undergone valvular
surgery more than 3 months previously, the risk in stop-
ping anticoagulation is very low (4–10 thromboembolic
episodes for 100 patient-years) [20, 21]. In contrast, in
the early phase after heart surgery, strokes are, even in the
presence of anticoagulation, quite frequent (2% of patients
in the first 10 days after cardiac surgery) [22]. Patients
with prosthetic valves may have subclinical cerebral
microembolization [21]. In our study, thromboembolic
events were very rare . However, for all the reasons above,
in patients not bleeding, heparin should be administered
as soon as possible.
We planned to study and we analyzed separately
Valves and CABG. This was due to the fact that patients
characteristics, surgical procedures and medication during
CBP are different. These differences are not irrelevant,
since they affect the tendency to bleed postoperatively,
as shown in the multivariate model of the postoperative
bleeding tendency. Most importantly, however, the post-
operative management is different. Indeed in Valves the
anticoagulation is much more aggressive, targeting and
achieving higher (therapeutic) anticoagulation values,
beginning earlier anticoagulation and delivering more
heparin during the ICU stay, as described in the heparin
treatment protocol (ESM). Regarding the effects of the
POC, it is obvious that the outcomes depending on the
reduced time to get the results, outcomes are improved
by the POC in Valves and in CABG. It is also clear
that the outcomes, depending on the ability to iden-
tify patients in whom heparin can be safely initiated
early, can be improved mainly in Valves rather than in
CABG.
After this study, we implemented the use of the POC
device in our unit for Valves in the first 24 h. The transla-
tion from research into clinical routine can be difficult. We
have now two reference values for anticoagulation (for the
POC aPTT and for the Lab aPTT). All the quality control
measures (internal and external) require time and person-
nel. Whether the benefits of our research will be translated
into everyday clinical life remains to be demonstrated.
Whether other POC measures such as the activated co-
agulation time (ACT), the thromboelastogram (TEG) [1]
or the thrombolytic assessment systems (TAS), or systems
analyzing the number of platelets, such as the Coulter T540
or M16 [12], or platelet function, such as the PFA-100 and
the hemoSTATUS with short turnaround times will help
to decrease the perioperative blood loss has to be further
studied.
Our study has several limitations. First, blinding the
study groups was obviously impossible. However, it seems
improbable that the bleeding could have been intentionally
influenced. This is supported by the fact that interventions
against bleeding were absent in both groups. Second, we
did not perform POC aPTT in the Lab group. POC tests
have to be performed at the bedside with whole blood only
a few seconds after venipuncture. Blinding of the team
in charge of the patient would have been almost impossi-
ble. The different time intervals to get the results between
the Lab aPTT and POC aPTT with this design could not
have been taken in account. As a consequence, we per-
formed more coagulation assessments in the POC group.
This could have biased the results in favor of the POC
group. However, the main difference in blood loss was ob-
served during the first 8 h, when only one coagulation as-
sessment was performed in most patients, which should
minimize the possible bias. Third, the power calculation
for CABG was based on a SD of the thoracic blood loss
smaller than finally measured. This could have resulted in
an underpowered study. However, the thoracic blood loss
and the hemoglobin at ICU discharge, as well as the num-
ber of patients needing transfusions, were almost identical
in both groups. We would have had to include more than
8,000 patients for the blood loss and almost 1,000 patients
for the number of transfused patients to confirm potential
clinically insignificant differences between the two groups.
Fourth, we cannot rule out the possibility that rare events,
such as major extrathoracic hemorrhages or thromboem-
bolic events were not increased. We would have needed ap-
proximately 2,500 patients to exclude an increase from 2%
to 4% of these events. Fifth, we did not further analyze the
differences between the Lab aPTT and the POC aPTT. This
question was specifically addressed in a previous paper [7].
In conclusion, in this randomized, open, controlled
trial, in Valves but not in CABG, coagulation management
guided by POC aPTT results allowed the introduction of
heparin earlier and higher and more appropriate doses
could be administered. Furthermore POC aPTT seems to
better predict the postoperative bleeding tendency than
Lab aPTT. This allowed identification of patients that
underwent valvular surgery in whom heparin could be
initiated or withheld in a more appropriate way, hereby re-
ducing postoperative thoracic blood loss and transfusions.
Every third patient managed following the POC aPTT
results could avoid requiring transfusions.
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